Journal · Oncology · Updated 15 November 2026
JAMA Oncology
Read JAMA Oncology research on DeepDyve. No university library needed.
JAMA Oncology, published by the American Medical Association, has covered cancer research since 2015. Its papers include clinical trials, cohort studies, meta-analyses and reviews on the treatment of lung, breast, prostate and other cancers, from immunotherapy and radiotherapy to biomarkers such as circulating tumor DNA. A DeepDyve subscription lets you read it in full, alongside millions of articles from other journals licensed from publishers including the American Medical Association.
Then $59 a month or $499 a year. A credit card is required; cancel during the trial and you won’t be charged. You read articles online; PDFs are sold separately.
Personal plans aren’t for business use. Reading for work? See Enterprise.
JAMA Oncology at a glance
- Full title
- JAMA Oncology
- Abbreviation (NLM)
- JAMA Oncol
- Publisher
- American Medical Association
- Print ISSN
- 2374-2437
- Online ISSN (eISSN)
- 2374-2445
- First published
- 2015
- Subjects
- Neoplasms
- Access model
- Subscription
- On DeepDyve
- Research articles; availability varies by article
Ways to access JAMA Oncology
JAMA Oncology is a subscription journal. To read its articles, look for the authors’ manuscript, check a library, or read them on DeepDyve.
- The authors’ accepted manuscript. JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository.
- NIH-funded research. For papers accepted on or after July 1, 2025, the US National Institutes of Health requires the accepted manuscript in PubMed Central, free with no embargo from the official publication date.
- A library. Your university, hospital or public library may subscribe to JAMA Oncology. Check its journal list and whether it offers remote access.
- DeepDyve. Read JAMA Oncology articles online for $59 a month or $499 a year after a free first month. Articles marked LitStream below are in DeepDyve’s LitStream collection, which a subscription lets you read online. PDFs are sold separately, and availability varies by article.
Sources: AMA on JAMA Network’s manuscript policy; NIH Public Access Policy.
Recent JAMA Oncology research worth reading
Published May to July 2026. Summaries describe what the authors report.
-
PD-(L)1 Inhibitor Monotherapy vs Chemoimmunotherapy for Advanced NSCLC With High PD-L1 Expression
In a meta-analysis of 24 randomized clinical trials with 5546 patients with advanced non-small cell lung cancer and PD-L1 expression of 50% or higher, the authors found chemoimmunotherapy was associated with significantly longer overall and progression-free survival than PD-(L)1 inhibitor monotherapy.
Di Federico et al. · JAMA Oncology, published online July 1, 2026 · DOI 10.1001/jamaoncol.2026.1548
-
Rates of Systemic Treatment for Metastatic Non–Small Cell Lung Cancer Among Older Adults
In a cohort study of more than 250,000 older patients with metastatic non-small cell lung cancer from 2006 through 2021, the authors report that only 46.8% ever received systemic therapy, with minimal increase over time, and that referral to an oncologist and low comorbidity burden were among the factors associated with treatment.
Fox et al. · JAMA Oncology, published online July 1, 2026 · DOI 10.1001/jamaoncol.2026.1080
-
Circulating Tumor DNA in Early Breast Cancer
This review covers circulating tumor DNA assays for minimal residual disease in early breast cancer, reporting that ctDNA positivity after curative-intent therapy is strongly associated with later distant recurrence, while evidence that ctDNA-guided management improves outcomes remains limited.
JAMA Oncology, May 2026 · DOI 10.1001/jamaoncol.2026.1465
-
Single-Fraction Stereotactic Body Radiotherapy for Localized Prostate Cancer
In a phase 1/2 nonrandomized trial of 45 patients with localized prostate cancer given stereotactic body radiotherapy as a single 19 Gy fraction, the authors report that estimated 3-year biochemical relapse-free survival met the predefined primary end point and that treatment was well tolerated.
JAMA Oncology, June 2026 · DOI 10.1001/jamaoncol.2026.1886
-
Cardiac Risk After Heart-Sparing Breast Radiotherapy
In a cross-sectional study of 4908 patients with breast cancer, 2223 of them left-sided, treated with heart-sparing radiotherapy, the authors found that a higher maximum dose to the left anterior descending coronary artery was independently associated with cardiac events, whereas whole-heart dose was not.
JAMA Oncology, July 2026 · DOI 10.1001/jamaoncol.2026.2066
Related journals
Questions about JAMA Oncology
How can I read JAMA Oncology articles without a subscription?
JAMA Network lets authors post the accepted manuscript of original research in a repository of their choice on the day of publication. Search the title in PubMed Central, Google Scholar or the authors’ university repository. Your library may also subscribe. DeepDyve lets you read JAMA Oncology articles online for $59 a month or $499 a year after a free first month.
What is the abbreviation for JAMA Oncology?
JAMA Oncology’s NLM (PubMed) abbreviation is JAMA Oncol.
What is the ISSN of JAMA Oncology?
The print ISSN is 2374-2437 and the online ISSN is 2374-2445.
Is JAMA Oncology open access?
JAMA Oncology articles are published under the subscription model; none of the 339 articles it published from January 1 to November 14, 2026 carry a Creative Commons license in Crossref.
JAMA Oncology articles on DeepDyve are licensed from the American Medical Association. Journal facts as of 15 November 2026.
Start reading JAMA Oncology today
One month free, then less than $2 a day. JAMA Oncology, plus millions of articles from thousands of journals.




